NO976122L - AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes - Google Patents
AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendesInfo
- Publication number
- NO976122L NO976122L NO976122A NO976122A NO976122L NO 976122 L NO976122 L NO 976122L NO 976122 A NO976122 A NO 976122A NO 976122 A NO976122 A NO 976122A NO 976122 L NO976122 L NO 976122L
- Authority
- NO
- Norway
- Prior art keywords
- assay method
- ligand antibodies
- phase ligand
- phase
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP18848095 | 1995-06-30 | ||
US08/649,100 US6114507A (en) | 1995-06-30 | 1996-05-17 | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
PCT/JP1996/001820 WO1997002290A1 (fr) | 1995-06-30 | 1996-07-01 | ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR |
Publications (3)
Publication Number | Publication Date |
---|---|
NO976122D0 NO976122D0 (no) | 1997-12-29 |
NO976122L true NO976122L (no) | 1998-02-27 |
NO324120B1 NO324120B1 (no) | 2007-08-27 |
Family
ID=26504954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19976122A NO324120B1 (no) | 1995-06-30 | 1997-12-29 | Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0842948B1 (no) |
JP (1) | JP3925663B2 (no) |
CN (1) | CN1196733A (no) |
AU (1) | AU724856B2 (no) |
CA (1) | CA2225852C (no) |
NO (1) | NO324120B1 (no) |
NZ (1) | NZ311174A (no) |
WO (1) | WO1997002290A1 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777540B1 (en) | 1996-09-02 | 2004-08-17 | Ko Okumura | Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand |
US5858990A (en) * | 1997-03-04 | 1999-01-12 | St. Elizabeth's Medical Center | Fas ligand compositions for treatment of proliferative disorders |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
US6204055B1 (en) * | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
EP1029550A4 (en) | 1997-11-10 | 2001-09-26 | Mochida Pharm Co Ltd | PREVENTIVE AND THERAPEUTIC DRUGS FOR DIFFUSED PULMONARY CONDITIONS |
ATE357931T1 (de) | 1998-02-06 | 2007-04-15 | Mochida Pharm Co Ltd | Mittel zur prävention/behandlung entzündlicher darmerkrankungen |
WO1999058150A1 (fr) * | 1998-05-14 | 1999-11-18 | Mochida Pharmaceutical Co., Ltd. | Agents preventifs/remedes contre la cirrhose du foie |
DE69932434D1 (de) * | 1998-05-29 | 2006-08-31 | Mochida Pharm Co Ltd | Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten |
JP4734739B2 (ja) * | 2000-09-29 | 2011-07-27 | 東レ株式会社 | 哺乳動物のガン抑制方法 |
DE60315815T2 (de) * | 2002-03-21 | 2008-05-21 | Eli Lilly And Co., Indianapolis | ANTAGONISTISCHE HUMANE ANTI-hFAS-LIGAND-ANTIKÖRPER UND FRAGMENTE DAVON |
EP1499352A4 (en) * | 2002-04-12 | 2006-10-11 | Medimmune Inc | ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES |
AR040778A1 (es) * | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
CA2510180C (en) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
KR20120035234A (ko) * | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
WO2005012363A1 (ja) * | 2003-08-01 | 2005-02-10 | Mochida Pharmaceutical Co., Ltd. | 標的化された炎症惹起剤 |
AU2007341631B9 (en) | 2006-12-28 | 2012-10-04 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo |
PT2231708E (pt) * | 2007-12-12 | 2015-07-30 | Pincell Srl | Remédios para pênfigo contendo anticorpos anti-ligando de faz |
CN101965403B (zh) | 2008-01-29 | 2013-07-03 | 株式会社抗体研究所 | A型肉毒杆菌毒素中和组合物及人抗a型肉毒杆菌毒素抗体 |
PT2376536E (pt) | 2008-12-12 | 2015-05-11 | Pincell Srl | Remédios para pênfigo contendo anticorpos anti-ligando de faz |
WO2011010156A1 (en) * | 2009-07-21 | 2011-01-27 | Queen Mary & Westfield College | Fas (apo-1, cd95) targeted platforms for intracellular drug delivery |
JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
RU2744836C2 (ru) * | 2014-05-08 | 2021-03-16 | Новодиакс, Инк. | Прямой иммуногистохимический анализ |
EP3076179A1 (en) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnosis and treatment of low grade gliomas |
JP6884785B2 (ja) * | 2015-09-23 | 2021-06-09 | アポジェニックス アーゲー | 抗cd95l抗体 |
LT3592392T (lt) * | 2017-03-10 | 2024-01-25 | University Of Louisville Research Foundation, Inc. | Fasl modifikuotos biomedžiagos su imunomoduliacine funkcija |
CN116888257A (zh) * | 2022-01-21 | 2023-10-13 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2174132A1 (en) * | 1993-10-14 | 1995-04-20 | Immunex Corporation | Fas antagonists and uses thereof |
JPH08127594A (ja) * | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Fas抗原に結合する新規蛋白質およびそれをコードするDNA |
JPH09508009A (ja) * | 1994-01-07 | 1997-08-19 | イミュネックス・コーポレーション | Fas抗原を結合するリガンド |
JP3451092B2 (ja) * | 1995-03-20 | 2003-09-29 | 康 奥村 | Fasリガンドに特異的に反応するモノクローナル抗体及びその製造方法 |
-
1996
- 1996-07-01 AU AU62435/96A patent/AU724856B2/en not_active Ceased
- 1996-07-01 EP EP96921136A patent/EP0842948B1/en not_active Expired - Lifetime
- 1996-07-01 CA CA002225852A patent/CA2225852C/en not_active Expired - Fee Related
- 1996-07-01 NZ NZ311174A patent/NZ311174A/en not_active IP Right Cessation
- 1996-07-01 JP JP50498997A patent/JP3925663B2/ja not_active Expired - Fee Related
- 1996-07-01 CN CN96196690A patent/CN1196733A/zh active Pending
- 1996-07-01 WO PCT/JP1996/001820 patent/WO1997002290A1/ja active IP Right Grant
-
1997
- 1997-12-29 NO NO19976122A patent/NO324120B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
JP3925663B2 (ja) | 2007-06-06 |
EP0842948A4 (en) | 2004-12-15 |
WO1997002290A1 (fr) | 1997-01-23 |
NO976122D0 (no) | 1997-12-29 |
NO324120B1 (no) | 2007-08-27 |
AU6243596A (en) | 1997-02-05 |
CA2225852C (en) | 2009-04-14 |
AU724856B2 (en) | 2000-10-05 |
EP0842948B1 (en) | 2009-04-22 |
EP0842948A1 (en) | 1998-05-20 |
CA2225852A1 (en) | 1997-01-23 |
NZ311174A (en) | 1999-04-29 |
CN1196733A (zh) | 1998-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO976122L (no) | AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes | |
NO996551D0 (no) | Forbedrete anti-IgE-antistoffer og fremgangsmåte for forbedring av polypeptider | |
ID19197A (id) | Pesawat pengolah informasi dan metode pengolah informasi | |
DE69632366D1 (de) | Probenfördereinrichtung | |
DE69732511D1 (de) | Verarbeitungsverfahren für Signale von Objekten mit sich bewegenden Teilen und Echographie-Vorrichtung dafür | |
NO962346D0 (no) | Humaniserte antistoffer og anvendelser derav | |
DK0825946T3 (da) | Fremgangsmåde til lastning og behandling af hydrocarboner | |
NO963371D0 (no) | Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det | |
FI101829B1 (fi) | Biospesifinen määritysmenetelmä | |
DE69638207D1 (de) | Prozessor und Verarbeitungsverfahren für Dokumente | |
DE69427123T2 (de) | Screeningverfahren für katalytische nicht-enzym-polypeptide und-proteine | |
EP0645630A3 (en) | Method for determining the presence of a pivka and reagent therefor. | |
EP0870826A4 (en) | NEW PROTEINS AND MONOCLONAL ANTIBODIES AGAINST THESE | |
DE69608277T2 (de) | Probenanalysegerät | |
DE69409379D1 (de) | Ultraschallabtastgerät und -verfahren | |
EP0699909A3 (en) | Method for the determination of fibrinogen and reagent for its determination | |
KR970703146A (ko) | 류마티스성 관절염의 치료방법 및 시약(method and reagents for the treatment of rheumatoid arthritis) | |
DE69426354D1 (de) | Reagenz zur bestimmung von glucose | |
ZA944024B (en) | Immunoassay reagents and methods for detecting brequinar and analoges | |
DK0780388T3 (da) | 5HT1Dalfa og 5HT2A ligander | |
DE69618904T2 (de) | Probenanalyse | |
FI931151A (fi) | Biospesifinen määritysmenetelmä | |
FI971754A0 (fi) | Vasta-ainereagenssi kalvoja irtauttavan aortan pullistuman osittamiseksi ja sen käyttö | |
KR970001553A (ko) | 인간 파르보비루스의 검출 방법 및 이를 위한 시약 | |
DE69322179D1 (de) | Verfahren und Reagenzien für Immunoassay |